Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: Nat Med. 2013 Apr 14;19(5):619–625. doi: 10.1038/nm.3175

Figure 5.

Figure 5

Summary, including clinically deployable markers and potential subtype-guided therapies for CRC. (a) Salient characteristics of the six CRC subtypes. Int, intermediate DFS; Either, either crypt top or base; NA, no clear association. (b) CRC subtype phenotypes correlated with colon-crypt location and Wnt signaling. (c) Summary of subtype-specific candidate biomarkers (CRCassigner-7) that were tested using qRT-PCR and immunohistochemistry (IHC), and (d) subtype guided therapeutic strategies suggested by the association studies. ZEB1 was not useful for qRT-PCR because ZEB1 is expressed both by fibroblast and tumor cells. The expression of ZEB1 specifically in tumor cells was evaluated using immunohistochemistry as in Figure 1c. TBD, to be determined.